Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Celgene Corp., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Celgene Corp. debt to equity ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Celgene Corp. debt to capital ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Celgene Corp. debt to assets ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Celgene Corp. financial leverage ratio decreased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Celgene Corp. interest coverage ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Debt to Equity
Celgene Corp., debt to equity calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Short-term borrowings and current portion of long-term debt | 1,498) | —) | 500) | 501) | 502) | 1,497) | —) | —) | 1,400) | 500) | 500) | 501) | 501) | —) | —) | —) | 1,200) | 1,363) | 504) | 606) | 100) | 192) | 870) | |||||||
| Long-term debt, net of discount, excluding current portion | 18,289) | 19,790) | 19,781) | 19,769) | 19,742) | 19,754) | 20,271) | 15,838) | 12,874) | 13,783) | 13,784) | 13,789) | 13,803) | 14,312) | 14,268) | 14,250) | 14,298) | 6,256) | 6,303) | 6,266) | 6,737) | 6,743) | 4,224) | |||||||
| Total debt | 19,787) | 19,790) | 20,281) | 20,270) | 20,244) | 21,251) | 20,271) | 15,838) | 14,274) | 14,283) | 14,284) | 14,289) | 14,304) | 14,312) | 14,268) | 14,250) | 15,498) | 7,619) | 6,807) | 6,872) | 6,837) | 6,936) | 5,094) | |||||||
| Stockholders’ equity | 12,087) | 10,051) | 8,165) | 6,161) | 4,860) | 3,430) | 5,172) | 6,921) | 9,850) | 8,445) | 7,644) | 6,599) | 5,650) | 5,549) | 5,075) | 5,919) | 5,376) | 6,322) | 6,765) | 6,525) | 5,768) | 4,851) | 4,485) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity1 | 1.64 | 1.97 | 2.48 | 3.29 | 4.17 | 6.20 | 3.92 | 2.29 | 1.45 | 1.69 | 1.87 | 2.17 | 2.53 | 2.58 | 2.81 | 2.41 | 2.88 | 1.21 | 1.01 | 1.05 | 1.19 | 1.43 | 1.14 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.73 | 2.84 | 3.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.41 | 1.56 | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.54 | 0.32 | 0.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.50 | 5.68 | 6.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.19 | 1.15 | 1.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.50 | 0.48 | 0.50 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.97 | 0.96 | 0.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.81 | 0.78 | 0.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.07 | 0.07 | 0.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.58 | 0.66 | 0.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Debt to equity = Total debt ÷ Stockholders’ equity
= 19,787 ÷ 12,087 = 1.64
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Celgene Corp. debt to equity ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Debt to Capital
Celgene Corp., debt to capital calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Short-term borrowings and current portion of long-term debt | 1,498) | —) | 500) | 501) | 502) | 1,497) | —) | —) | 1,400) | 500) | 500) | 501) | 501) | —) | —) | —) | 1,200) | 1,363) | 504) | 606) | 100) | 192) | 870) | |||||||
| Long-term debt, net of discount, excluding current portion | 18,289) | 19,790) | 19,781) | 19,769) | 19,742) | 19,754) | 20,271) | 15,838) | 12,874) | 13,783) | 13,784) | 13,789) | 13,803) | 14,312) | 14,268) | 14,250) | 14,298) | 6,256) | 6,303) | 6,266) | 6,737) | 6,743) | 4,224) | |||||||
| Total debt | 19,787) | 19,790) | 20,281) | 20,270) | 20,244) | 21,251) | 20,271) | 15,838) | 14,274) | 14,283) | 14,284) | 14,289) | 14,304) | 14,312) | 14,268) | 14,250) | 15,498) | 7,619) | 6,807) | 6,872) | 6,837) | 6,936) | 5,094) | |||||||
| Stockholders’ equity | 12,087) | 10,051) | 8,165) | 6,161) | 4,860) | 3,430) | 5,172) | 6,921) | 9,850) | 8,445) | 7,644) | 6,599) | 5,650) | 5,549) | 5,075) | 5,919) | 5,376) | 6,322) | 6,765) | 6,525) | 5,768) | 4,851) | 4,485) | |||||||
| Total capital | 31,874) | 29,841) | 28,446) | 26,431) | 25,104) | 24,681) | 25,443) | 22,759) | 24,124) | 22,728) | 21,928) | 20,889) | 19,954) | 19,861) | 19,343) | 20,169) | 20,873) | 13,941) | 13,572) | 13,396) | 12,606) | 11,787) | 9,579) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital1 | 0.62 | 0.66 | 0.71 | 0.77 | 0.81 | 0.86 | 0.80 | 0.70 | 0.59 | 0.63 | 0.65 | 0.68 | 0.72 | 0.72 | 0.74 | 0.71 | 0.74 | 0.55 | 0.50 | 0.51 | 0.54 | 0.59 | 0.53 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 1.27 | 1.30 | 1.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.73 | 0.74 | 0.75 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.59 | 0.61 | 0.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.35 | 0.24 | 0.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.82 | 0.85 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.54 | 0.54 | 0.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.33 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.49 | 0.49 | 0.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.45 | 0.44 | 0.43 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.06 | 0.07 | 0.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.37 | 0.40 | 0.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Debt to capital = Total debt ÷ Total capital
= 19,787 ÷ 31,874 = 0.62
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Celgene Corp. debt to capital ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Debt to Assets
Celgene Corp., debt to assets calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Short-term borrowings and current portion of long-term debt | 1,498) | —) | 500) | 501) | 502) | 1,497) | —) | —) | 1,400) | 500) | 500) | 501) | 501) | —) | —) | —) | 1,200) | 1,363) | 504) | 606) | 100) | 192) | 870) | |||||||
| Long-term debt, net of discount, excluding current portion | 18,289) | 19,790) | 19,781) | 19,769) | 19,742) | 19,754) | 20,271) | 15,838) | 12,874) | 13,783) | 13,784) | 13,789) | 13,803) | 14,312) | 14,268) | 14,250) | 14,298) | 6,256) | 6,303) | 6,266) | 6,737) | 6,743) | 4,224) | |||||||
| Total debt | 19,787) | 19,790) | 20,281) | 20,270) | 20,244) | 21,251) | 20,271) | 15,838) | 14,274) | 14,283) | 14,284) | 14,289) | 14,304) | 14,312) | 14,268) | 14,250) | 15,498) | 7,619) | 6,807) | 6,872) | 6,837) | 6,936) | 5,094) | |||||||
| Total assets | 41,363) | 39,183) | 37,639) | 35,480) | 34,215) | 33,444) | 34,556) | 30,141) | 31,736) | 30,306) | 28,820) | 28,086) | 26,754) | 26,562) | 25,964) | 27,053) | 27,369) | 17,746) | 17,481) | 17,340) | 16,403) | 15,602) | 12,705) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets1 | 0.48 | 0.51 | 0.54 | 0.57 | 0.59 | 0.64 | 0.59 | 0.53 | 0.45 | 0.47 | 0.50 | 0.51 | 0.53 | 0.54 | 0.55 | 0.53 | 0.57 | 0.43 | 0.39 | 0.40 | 0.42 | 0.44 | 0.40 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.65 | 0.65 | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.50 | 0.52 | 0.52 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.43 | 0.45 | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.29 | 0.19 | 0.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.40 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.42 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.19 | 0.19 | 0.20 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.31 | 0.32 | 0.31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.03 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.31 | 0.30 | 0.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.05 | 0.05 | 0.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.30 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Debt to assets = Total debt ÷ Total assets
= 19,787 ÷ 41,363 = 0.48
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Celgene Corp. debt to assets ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Financial Leverage
Celgene Corp., financial leverage calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Total assets | 41,363) | 39,183) | 37,639) | 35,480) | 34,215) | 33,444) | 34,556) | 30,141) | 31,736) | 30,306) | 28,820) | 28,086) | 26,754) | 26,562) | 25,964) | 27,053) | 27,369) | 17,746) | 17,481) | 17,340) | 16,403) | 15,602) | 12,705) | |||||||
| Stockholders’ equity | 12,087) | 10,051) | 8,165) | 6,161) | 4,860) | 3,430) | 5,172) | 6,921) | 9,850) | 8,445) | 7,644) | 6,599) | 5,650) | 5,549) | 5,075) | 5,919) | 5,376) | 6,322) | 6,765) | 6,525) | 5,768) | 4,851) | 4,485) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Financial leverage1 | 3.42 | 3.90 | 4.61 | 5.76 | 7.04 | 9.75 | 6.68 | 4.36 | 3.22 | 3.59 | 3.77 | 4.26 | 4.73 | 4.79 | 5.12 | 4.57 | 5.09 | 2.81 | 2.58 | 2.66 | 2.84 | 3.22 | 2.83 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 5.45 | 5.50 | 5.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.25 | 3.44 | 2.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 1.89 | 1.66 | 1.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 11.20 | 13.91 | 15.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.87 | 2.79 | 2.86 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.67 | 2.55 | 2.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 3.10 | 3.04 | 2.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 1.27 | 1.26 | 1.25 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 2.62 | 2.62 | 2.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.33 | 1.35 | 1.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.93 | 2.02 | 2.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Financial leverage = Total assets ÷ Stockholders’ equity
= 41,363 ÷ 12,087 = 3.42
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Celgene Corp. financial leverage ratio decreased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |
Interest Coverage
Celgene Corp., interest coverage calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net income (loss) | 1,691) | 1,571) | 1,545) | 1,073) | 1,082) | 1,045) | 846) | (81) | 988) | 1,101) | 932) | 429) | 171) | 598) | 801) | 561) | (34) | 356) | 719) | 614) | 509) | 598) | 280) | |||||||
| Add: Income tax expense | 226) | 250) | 269) | 44) | 296) | 262) | 184) | 1,212) | 3) | 77) | 82) | 70) | 85) | 97) | 121) | 185) | 14) | 115) | 108) | 97) | 69) | 109) | 53) | |||||||
| Add: Interest expense | 190) | 192) | 192) | 190) | 193) | 192) | 166) | 142) | 127) | 126) | 127) | 127) | 128) | 123) | 122) | 125) | 89) | 48) | 49) | 52) | 54) | 42) | 29) | |||||||
| Earnings before interest and tax (EBIT) | 2,107) | 2,013) | 2,006) | 1,307) | 1,571) | 1,499) | 1,196) | 1,273) | 1,118) | 1,304) | 1,141) | 626) | 385) | 818) | 1,044) | 870) | 69) | 519) | 876) | 763) | 631) | 748) | 362) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Interest coverage1 | 9.73 | 8.99 | 8.32 | 7.52 | 7.99 | 8.11 | 8.72 | 9.26 | 8.26 | 6.80 | 5.88 | 5.74 | 6.26 | 6.11 | 6.53 | 7.51 | 9.37 | 13.76 | 15.40 | 14.22 | — | — | — | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||
| Amgen Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Interest coverage
= (EBITQ3 2019
+ EBITQ2 2019
+ EBITQ1 2019
+ EBITQ4 2018)
÷ (Interest expenseQ3 2019
+ Interest expenseQ2 2019
+ Interest expenseQ1 2019
+ Interest expenseQ4 2018)
= (2,107 + 2,013 + 2,006 + 1,307)
÷ (190 + 192 + 192 + 190)
= 9.73
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Celgene Corp. interest coverage ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019. |